Improvement of digestive health and reduction in proteobacterial populations in the gut microbiota of cystic fibrosis patients using a Lactobacillus reuteri probiotic preparation: A double blind prospective study

Journal of Cystic Fibrosis

Volumn 13, Issue 6, 2014, Pages 716-722

  del Campo, Rosa ^a,b,c   Garriga, María ^a   Pérez Aragón, Ana ^d   Guallarte, Pilar ^e   Lamas, Adelaida ^a,b   Máiz, Luis ^a   Bayón, Carmen ^a   Roy, Garbiñe ^a   Cantón, Rafael ^a,b,c   Zamora, Javier ^a,b,f   Baquero, Fernando ^a,b,f   Suárez, Lucrecia ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b INSTITUTO RAMÓN Y CAJAL DE INVESTIGACIÓN SANITARIA IRYCIS   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL DE SABADELL   (Spain)

^f CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

Author keywords

Digestive health; Intestinal microbiota; Lactobacillus reuteri; Probiotics

Indexed keywords

CALGRANULIN; PLACEBO; PROBIOTIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBACTERIAL ACTIVITY; ARTICLE; BODY MASS; CHILD; CLINICAL ARTICLE; COLONY FORMING UNIT; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DIGESTIVE FUNCTION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSBIOSIS; FECES ANALYSIS; FEMALE; FIRMICUTES; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL QUALITY OF LIFE INDEX; HUMAN; INTESTINE FLORA; LACTOBACILLUS REUTERI; LIPID ABSORPTION; LUNG DISEASE; MALE; METAGENOMICS; MICROBIAL DIVERSITY; MICROBIOME; MULTICENTER STUDY; NONHUMAN; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PANCREAS INSUFFICIENCY; PROSPECTIVE STUDY; PROTEOBACTERIA; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; SHORT FORM 12; TREATMENT DURATION; VAGINA CANDIDIASIS; COMPLICATION; FECES; INTESTINE; ISOLATION AND PURIFICATION; MICROBIOLOGY; MICROFLORA; YOUNG ADULT;

ADOLESCENT; ADULT; CHILD; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; FECES; FEMALE; HUMANS; INTESTINES; LACTOBACILLUS REUTERI; MALE; METAGENOMICS; MICROBIOTA; PROBIOTICS; PROSPECTIVE STUDIES; PROTEOBACTERIA; YOUNG ADULT;

EID: 84911974049     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2014.02.007     Document Type: Article

References (25)

1. O'Sullivan B.P., Baker D., Leung K.G., Reed G., Baker S.S., Borowitz D. Evolution of pancreatic function during the first year in infants with cystic fibrosis. J Pediatr 2013, 162:808-812.
2. Steinkamp G., Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002, 57:596-601.
3. Gaskin K.J. Nutritional care in children with cystic fibrosis: are our patients becoming better?. Eur J Clin Nutr 2013, 67:558-564.
4. Lee J.M., Leach S.T., Katz T., Day A.S., Jaffe A., Ooi C.Y. Update of faecal markers of inflammation in children with cystic fibrosis. Mediators Inflamm 2012, 2012:948367.
5. Ranganathan S.C., Parsons F., Gangell C., Brennan S., Stick S.M., Sly P.D. Australian Respiratory Early Surveillance Team for Cystic Fibrosis. Evolution of pulmonary inflammation and nutritional status in infants and young children with cystic fibrosis. Thorax 2011, 66:408-413.
6. Bruzzese E., Raia V., Gaudiello G., Polito G., Buccigrossi V., Formicola V., et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Aliment Pharmacol Ther 2004, 20:813-819.
7. Bruzzese E., Raia V., Spagnuolo M.I., Volpicelli M., De Marco G., Maiuri L., et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clin Nutr 2007, 26:322-328.
8. Infante Pina D., Redecillas Ferreiro S., Torrent Vernetta A., Segarra Cantón O., Maldonado Smith M., et al. Improvement of intestinal function in cystic fibrosis patients using probiotics. An Pediatr (Barc) 2008, 69:501-505.
9. Weiss B., Bujanover Y., Yahav Y., Vilozni D., Fireman E., Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatr Pulmonol 2010, 45:536-540.
10. Madan J.C., Koestler D.C., Stanton B.A., Davidson L., Moulton L.A., Housman M.L., et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio 2012, 3. [pii: e00251-12].
11. Sandblom G., Videhult P., Karlson B.M., Wollert S., Ljungdahl M., Darkahi B., et al. Validation of Gastrointestinal Quality of Life Index in Swedish for assessing the impact of gallstones on health-related quality of life. Value Health 2009, 12:181-184.
12. Kontodimopoulos N., Pappa E., Niakas D., Tountas Y. Validity of SF-12 summary scores in a Greek general population. Health Qual Life Outcomes 2007, 5:55.
13. Cohen J. Statistical power analysis for the behavioral sciences 1977, 2nd ed.
14. Schippa S., Iebba V., Santangelo F., Gagliardi A., De Biase R.V., Stamato A., et al. Cystic fibrosis transmembrane conductance regulator (CFTR) allelic variants relate to shifts in faecal microbiota of cystic fibrosis patients. PLoS One 2013, 17:e61176.
15. Duytschaever G., Huys G., Bekaert M., Boulanger L., De Boeck K., Vandamme P. Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros 2013, 12:206-215.
16. Scanlan P.D., Buckling A., Kong W., Wild Y., Lynch S.V., Harrison F. Gut dysbiosis in cystic fibrosis. J Cyst Fibros 2012, 11:454-455.
17. MacPhee R.A., Hummelen R., Bisanz J.E., Miller W.L., Reid G. Probiotic strategies for the treatment and prevention of bacterial vaginosis. Expert Opin Pharmacother 2010, 11:2985-2995.
18. Rogers G.B., Carroll M.P., Hoffman L.R., Walker A.W., Fine D.A., Bruce K.D. Comparing the microbiota of the cystic fibrosis lung and human gut. Gut Microbes 2010, 1:85-93.
19. Barfod K.K., Roggenbuck M., Hansen L.H., Schjørring S., Larsen S.T., Sørensen S.J., et al. The murine lung microbiome in relation to the intestinal and vaginal bacterial communities. BMC Microbiol 2013, 13:303.
20. Lozupone C.A., Stombaugh J.I., Gordon J.I., Jansson J.K., Knight R. Diversity, stability and resilience of the human gut microbiota. Nature 2012, 489:220-230.
21. Lynch S.V., Goldfarb K.C., Wild Y.K., Kong W., De Lisle R.C., Brodie E.L. Cystic fibrosis transmembrane conductance regulator knockout mice exhibit aberrant gastrointestinal microbiota. Gut Microbes 2013, 4:41-47.
22. Arumugam M., Raes J., Pelletier E., Le Paslier D., Yamada T., Mende D.R., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
23. Duytschaever G., Huys G., Bekaert M., Boulanger L., De Boeck K., Vandamme P. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol 2011, 77:8015-8024.
24. Iebba V., Santangelo F., Totino V., Nicoletti M., Gagliardi A., De Biase R.V., et al. Higher prevalence and abundance of Bdellovibrio bacteriovorus in the human gut of healthy subjects. PLoS One 2013, 8:e61608.
25. Baquero F., Tedim A.P., Coque T.M. Antibiotic resistance shaping multi-level population biology of bacteria. Front Microbiol 2013, 4:15.